EP 024297

Drug Profile

EP 024297

Alternative Names: EP-024297

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Nov 2016 Updated pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 11 Nov 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting® 2016; AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top